Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of 64-Cu Labeled Brain PET/MRI for MM-302, a Novel HER2 Targeting Agent, in Advanced HER2+ Cancer With Brain Metastases

NCT02735798 is registered in ClinicalTrials.gov with Pamela Munster as lead sponsor.

NCT NCT02735798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02735798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of 64-Cu Labeled Brain PET/MRI for MM-302, a Novel HER2 Targeting Agent, in Advanced HER2+ Cancer With Brain Metastases
Lead sponsor
Pamela Munster
Phase
Phase 1
Overall status
Withdrawn
Start date
April 30, 2016
Completion date
June 30, 2018
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, brain metastases, documented her2 overexpression, neurologically stable